Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model

Yeon Jung Kim, Jeonghyun Ahn, Soo Young Jeung, Dae Sun Kim, Ha Na Na, Young Joo Cho, Soo Hyeon Yun, Youngmee Jee, Eun Seok Jeon, Heuiran Lee, Jae Hwan Nam

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Coxsackieviruses are important human pathogens that induce myocarditis and pancreatitis. However, there are no vaccines or therapeutic reagents for their clinical treatment. Although RNA interference (RNAi)-based approaches to the prevention of viral production have been developed recently, limitations to the in vivo delivery systems and variations in the viral target sequences still hamper the strategy. In this study, to overcome these limitations, we have constructed recombinant lentivirus-delivered short hairpin RNAs (shRNAs) against sequences in highly conserved cis-acting replication element (CRE) within the 2C protein of coxsackievirus B3 (CVB3), designated MET-2C. A recombinant lentivirus, designated Met-2C lenti, was constructed that contains the MET-2C sequence, which acts as a shRNA. Met-2C lenti clearly reduced viral production in CVB3-infected cells in vitro. Moreover, the mice injected intraperitoneally with Met-2C lenti had significant reductions in viral titers, viral myocarditis, and proinflammatory cytokines after challenge with CVB3, compared with those in GFP lenti infected control mice. Moreover, Met-2C lenti improved survival rate compared with that of the GFP lenti infected control group. Therefore, Met-2C lenti is potentially a clinical therapeutic agent for the treatment of viral myocarditis.

Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalVirus Genes
Volume36
Issue number1
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Lentivirus
Enterovirus
Conserved Sequence
Myocarditis
Small Interfering RNA
Animal Models
RNA Interference
Pancreatitis
Vaccines
Cytokines
Control Groups
Therapeutics
Proteins

Keywords

  • Coxsackievirus
  • Lentivirus
  • Myocarditis
  • shRNA

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Virology

Cite this

Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model. / Kim, Yeon Jung; Ahn, Jeonghyun; Jeung, Soo Young; Kim, Dae Sun; Na, Ha Na; Cho, Young Joo; Yun, Soo Hyeon; Jee, Youngmee; Jeon, Eun Seok; Lee, Heuiran; Nam, Jae Hwan.

In: Virus Genes, Vol. 36, No. 1, 01.02.2008, p. 141-146.

Research output: Contribution to journalArticle

Kim, Yeon Jung ; Ahn, Jeonghyun ; Jeung, Soo Young ; Kim, Dae Sun ; Na, Ha Na ; Cho, Young Joo ; Yun, Soo Hyeon ; Jee, Youngmee ; Jeon, Eun Seok ; Lee, Heuiran ; Nam, Jae Hwan. / Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model. In: Virus Genes. 2008 ; Vol. 36, No. 1. pp. 141-146.
@article{c0a0b8a6fb9c48fcae08ffba0f767d01,
title = "Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model",
abstract = "Coxsackieviruses are important human pathogens that induce myocarditis and pancreatitis. However, there are no vaccines or therapeutic reagents for their clinical treatment. Although RNA interference (RNAi)-based approaches to the prevention of viral production have been developed recently, limitations to the in vivo delivery systems and variations in the viral target sequences still hamper the strategy. In this study, to overcome these limitations, we have constructed recombinant lentivirus-delivered short hairpin RNAs (shRNAs) against sequences in highly conserved cis-acting replication element (CRE) within the 2C protein of coxsackievirus B3 (CVB3), designated MET-2C. A recombinant lentivirus, designated Met-2C lenti, was constructed that contains the MET-2C sequence, which acts as a shRNA. Met-2C lenti clearly reduced viral production in CVB3-infected cells in vitro. Moreover, the mice injected intraperitoneally with Met-2C lenti had significant reductions in viral titers, viral myocarditis, and proinflammatory cytokines after challenge with CVB3, compared with those in GFP lenti infected control mice. Moreover, Met-2C lenti improved survival rate compared with that of the GFP lenti infected control group. Therefore, Met-2C lenti is potentially a clinical therapeutic agent for the treatment of viral myocarditis.",
keywords = "Coxsackievirus, Lentivirus, Myocarditis, shRNA",
author = "Kim, {Yeon Jung} and Jeonghyun Ahn and Jeung, {Soo Young} and Kim, {Dae Sun} and Na, {Ha Na} and Cho, {Young Joo} and Yun, {Soo Hyeon} and Youngmee Jee and Jeon, {Eun Seok} and Heuiran Lee and Nam, {Jae Hwan}",
year = "2008",
month = "2",
day = "1",
doi = "10.1007/s11262-007-0192-y",
language = "English (US)",
volume = "36",
pages = "141--146",
journal = "Virus Genes",
issn = "0920-8569",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model

AU - Kim, Yeon Jung

AU - Ahn, Jeonghyun

AU - Jeung, Soo Young

AU - Kim, Dae Sun

AU - Na, Ha Na

AU - Cho, Young Joo

AU - Yun, Soo Hyeon

AU - Jee, Youngmee

AU - Jeon, Eun Seok

AU - Lee, Heuiran

AU - Nam, Jae Hwan

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Coxsackieviruses are important human pathogens that induce myocarditis and pancreatitis. However, there are no vaccines or therapeutic reagents for their clinical treatment. Although RNA interference (RNAi)-based approaches to the prevention of viral production have been developed recently, limitations to the in vivo delivery systems and variations in the viral target sequences still hamper the strategy. In this study, to overcome these limitations, we have constructed recombinant lentivirus-delivered short hairpin RNAs (shRNAs) against sequences in highly conserved cis-acting replication element (CRE) within the 2C protein of coxsackievirus B3 (CVB3), designated MET-2C. A recombinant lentivirus, designated Met-2C lenti, was constructed that contains the MET-2C sequence, which acts as a shRNA. Met-2C lenti clearly reduced viral production in CVB3-infected cells in vitro. Moreover, the mice injected intraperitoneally with Met-2C lenti had significant reductions in viral titers, viral myocarditis, and proinflammatory cytokines after challenge with CVB3, compared with those in GFP lenti infected control mice. Moreover, Met-2C lenti improved survival rate compared with that of the GFP lenti infected control group. Therefore, Met-2C lenti is potentially a clinical therapeutic agent for the treatment of viral myocarditis.

AB - Coxsackieviruses are important human pathogens that induce myocarditis and pancreatitis. However, there are no vaccines or therapeutic reagents for their clinical treatment. Although RNA interference (RNAi)-based approaches to the prevention of viral production have been developed recently, limitations to the in vivo delivery systems and variations in the viral target sequences still hamper the strategy. In this study, to overcome these limitations, we have constructed recombinant lentivirus-delivered short hairpin RNAs (shRNAs) against sequences in highly conserved cis-acting replication element (CRE) within the 2C protein of coxsackievirus B3 (CVB3), designated MET-2C. A recombinant lentivirus, designated Met-2C lenti, was constructed that contains the MET-2C sequence, which acts as a shRNA. Met-2C lenti clearly reduced viral production in CVB3-infected cells in vitro. Moreover, the mice injected intraperitoneally with Met-2C lenti had significant reductions in viral titers, viral myocarditis, and proinflammatory cytokines after challenge with CVB3, compared with those in GFP lenti infected control mice. Moreover, Met-2C lenti improved survival rate compared with that of the GFP lenti infected control group. Therefore, Met-2C lenti is potentially a clinical therapeutic agent for the treatment of viral myocarditis.

KW - Coxsackievirus

KW - Lentivirus

KW - Myocarditis

KW - shRNA

UR - http://www.scopus.com/inward/record.url?scp=39049170153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049170153&partnerID=8YFLogxK

U2 - 10.1007/s11262-007-0192-y

DO - 10.1007/s11262-007-0192-y

M3 - Article

C2 - 18172750

AN - SCOPUS:39049170153

VL - 36

SP - 141

EP - 146

JO - Virus Genes

JF - Virus Genes

SN - 0920-8569

IS - 1

ER -